|View printer-friendly version|
|July 11, 2012 6:07 a.m.|
|Teva Announces Favorable United Kingdom Court Ruling In COPAXONE® Patent Litigation Proceeding|
JERUSALEM--(BUSINESS WIRE)--Jul. 11, 2012--
Any potential generic version of COPAXONE® would require a marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) before it could be commercialized.
Teva's Safe Harbor Statement under the